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Patients, n 308Effectiveness and tolerability of
guselkumab in patients with
psoriasis: A longitudinal Belgian




Ethnic origin, % (n)
White Caucasian 94.5 (291)
Mediterranean 3.6 (11)
North African 1.6 (5)
Asian 0.3 (1)










Cardiovascular events 7.8 (24)
Psoriatic arthritis 6.5 (20)
Diabetes 5.5 (17)
Dyslipidemia 3.9 (12)
Inflammatory bowel disease 1 (3)
Solid malignancies 0.7 (2)
Fibromyalgia 0.7 (2)
Sarcoidosis 0.3 (1)
Ethylic cirrhosis 0.3 (1)
Idiopathic pulmonary fibrosis 0.3 (1)
Erythema elevatum diutinum 0.3 (1)
Multiple myeloma 0.3 (1)
Psoriasis duration ( y), mean (range) 18.5 (1-64)
Initial PASI score, mean (range) 17.7 (3.4-37)
Exposure to biologic therapy before receiving
guselkumab, % (n)
Yes (bio-experienced group) 57.8 (178)
No (bio-naive group) 42.2 (130)
Side effects, % (n)
Fatigue 0.7 (2)
Headache 0.3 (1)
Joint pain 0.3 (1)
Bronchitis 0.3 (1)
Flu-like symptoms 0.3 (1)
Koebner phenomenon on tattoo 0.3 (1)
Injection site reaction 0.3 (1)
PASI, Psoriasis Area Severity Index; y, years.To the Editor: We conducted the first Belgian multi-
centric observational study that investigated the
long-term (up to week 88) effectiveness and tolera-
bility of guselkumab in the treatment of plaque-type
psoriasis. Guselkumab (Tremfya, Janssen Biotech,
Inc) is indicated for the treatment of moderate to
severe plaque psoriasis or active psoriatic arthritis
and binds selectively to interleukin 23p19.
Last year, we published a study that investigated
the short-term (up to week 16) effectiveness and
tolerability of guselkumab in a cohort of 112
Belgian patients, demonstrating good efficacy and
safety profile.1 We now collected data from 308
patients (40% female and 60% male) (Table I). The
mean age of the study population was 48.9 years,
and the mean duration of psoriasis was 18.5 years.
The main comorbidities were arterial hypertension
(12.3%), depression (10%), cardiovascular events
(7.8%), and psoriatic arthritis (6.5%). Among the
study population, 57.8% of the patients had already
received at least 1 biotherapy prior to receiving
guselkumab (bio-experienced group), whereas
42.2% patients received guselkumab as the first
biotherapy (bio-naive group). The mean absolute
Psoriasis Area Severity Index (PASI)
(mean 6 standard deviation) at initiation was
17.7 6 6.4 and decreased to 0.6 6 1.7 at week 88
(Fig 1, A). The percentage of patients who achieved
PASI 75, PASI 90, and PASI 100 at week 88 was
95.5%, 91%, and 73%, respectively (Fig 1, B).
The main bias of our study is that, of the 308
patients, only 44 reached week 88 and we do not
know if missing data represent patients with less or
more severe disease. The observed tolerance and
safety profile of guselkumab were good and fewer
than 1% of the patients reported minor side effects,
with the most frequently reported side effect being
fatigue (Table I). Our observations reinforce the data
published previously for phase III randomized
clinical trials VOYAGE 1 and 2 and NAVIGATE that
assessed the efficacy of guselkumab in psoriasis.2,3
Nowadays, the need for studies based on differentª 2021 by the American Academy of Dermatology, Inc. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig 1. Psoriasis disease activity under the treatment of
guselkumab. A, Absolute PASI over time. B, PASI 75, PASI
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16 Letterselected patients in randomized controlled trials.
Observational retrospective studies have been con-
ducted across different countries to assess the short-
term real-life effectiveness of guselkumab among
very small cohorts of patients with psoriasis, demon-
strating good safety and tolerability profile, a PASI 90
up to 73.9%, and a PASI 100 up to 43.5%.4 However, a
few studies based on the experience of different
clinics with guselkumab have been conducted past
the 1-year time point. A recently published study by
Maliyar et al5 reported that in a population of 79patients with psoriasis, 35 achieved a PASI 100 after
1.2 years of follow-up, with the most commonly
reported side effects being nasopharyngitis, head-
aches, upper respiratory tract infections, gastrointes-
tinal tissues, and arthralgia. As opposed to these
prior studies, our investigation was conducted
among a much larger number of patients with
psoriasis and showed better long-term effectiveness
in terms of PASI 75, PASI 90, and PASI 100 responses.
With this retrospective analysis, we hope to inform
clinicians about the short- and long-term effective-
ness and safety profile of guselkumab for treating
patients with psoriasis.
Pierre-Dominique Ghislain, MD,a Valerie Failla,
MD,b Jo Lambert, MD, PhD,c Rani Soenen, MD,c
Lynda Grine, MD,c Julio Tannous, MD,d,e
Françoise Guiot, MD,f Fabienne Willaert, MD,d
Hugues Fierens, MD,g Mark Vandaele, MD,h
Hugo Boonen, MD,i Julie Saerens, MD,i
Veronique Meuleman, MD,j Annelies Stockman,
MD,k Arno Belpaire, MD,k Sandra Swimberghe,
MD,l Linda Temmerman, MD,m Sam Dekeyser,
MD,m Jean-Michel Lambert, MD,n Virginie de
Schaetzen, MD,o,p Michel de la Brassinne, MD,q
and Farida Benhadou, MD, PhDd
From the Department of Dermatology, Cliniques
Saint-Luc, Universite Catholique de Louvain,
Brussels, Belgiuma; Departement of Derma-
tology, Clinique Andre Renard, Herstal, Bel-
giumb; Department of Head and Skin, Ghent
University, Ghent, Belgiumc; Department of
Dermatology, Erasme Hospital, Universite Libre
de Bruxelles, Brussels, Belgiumd; Department of
Dermatology, Saint George Hospital University
Medical Center, University of Balamand, Beirut,
Lebanone; Departement of Dermatology, Centre
medical St-Georges, Grez-Doiceau, Belgiumf;
Department of Dermatology, Clinique Saint-
Jean, Brussels, Belgiumg; Groepspraktijk Derma-
tologie Roeselare, Roeselare, Belgiumh; Depart-
ment of Dermatology, Heilig Hartziekenhuis
Mol, Mol, Belgiumi; Private Dermatology and
Trichology Clinic, Tielt, Belgiumj; Departement
of Dermatology, AZ Delta Ziekenhuis, Torhout,
Belgiumk; Skin and Laser Clinic, Antwerpen,
Belgiuml; Department of Dermatology, AZ Maria
Middelares, Gent, Belgiumm; Departement of
Dermatology, Private Practice Huy, Huy, Belgi-
umn; Department of Dermatology, Centre Hospi-
talier Universitaire Liege, Liege, Belgiumo;
Department of Dermatology, Centre Hospitalier
Universitaire Universite Catholique de Louvain
Namur, Namur, Belgiump; and Department of
JAAD INT
VOLUME 4
Letter 17Dermatology, Centre Hospitalier Universitaire-
Centre-Ville, University of Liege, Liege, Belgium.q
Funding sources: None.
IRB approval status: Institutional review board
approval was not required for this work.
Correspondence to: Farida Benhadou, MD, PhD,
Route de Lennik 8080, Anderlecht 1070, Belgium
E-mail: dr.farida.benhadou@gmail.com
Conflicts of interest
Dr Ghislain provides consultancy to, receives fees as a
speaker and/or investigator from, or receives grants from
Pfizer, MSD, AbbVie, Janssen, Serono, Leo, Novartis, UCB,
Amgen, Eli Lilly, Galderma, BMS, Meda, Maruho, Flen,
Menarini, Almirall, PellePharm, and Viatris. Dr Jo Lambert
has been an advisor/speaker for Janssen, Leo Pharma,
AbbVie, and Novartis. Dr Grine has been a speaker for
AbbVie. Dr Willaert has been an advisor/speaker for
Janssen, Leo Pharma, AbbVie, Celgene, and Novartis. Dr
Fierens has been an advisor for Janssen, Leo Pharma, and
Novartis. Dr Vandaele has been an advisor/speaker for
Janssen, Leo Pharma, and Novartis. Dr Boonen has been an
advisor/speaker for Celgene, Leo Pharma, Janssen-Cilag,
Lily, Novartis, UCB, Almirall, AbbVie, Fresenius Kabi,
Mylan, and Sanofi. Dr de Schaetzen has been an advisor/
speaker for AbbVie, Novartis, and Leo Pharma. Dr de la
Brassinne has received lecture and/or consultation fees
and/or travel reimbursement from AbbVie, Almirall,Amgen, Eli Lilly, Janssen, Leo Pharma, Novartis, and
Pfizer. Drs Failla, Soenen, Tannous, Guiot, Saerens,
Meuleman, Stockman, Belpaire, Swimberghe,
Temmerman, Dekeyser, Jean-Michel Lambert, and
Benhadou have no conflicts of interest to declare.REFERENCES
1. Benhadou F, Ghislain PD, Guiot F, et al. Real-life effectiveness
and short-term (16-week) tolerance of guselkumab for psori-
asis: a Belgian retrospective multicentre study. J Eur Acad
Dermatol Venereol. 2020;34(12):e837-e839.
2. Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of
guselkumab in patients with psoriasis who have an inade-
quate response to ustekinumab: results of the randomized,
double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;
178(1):114-123.
3. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of
guselkumab, an anti-interleukin-23 monoclonal antibody,
compared with adalimumab for the continuous treatment of
patients with moderate to severe psoriasis: results from
the phase III, double-blinded, placebo- and active
comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol.
2017;76(3):405-417.
4. Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A.
Guselkumab in moderate to severe psoriasis in routine clinical
care: an Italian 44-week real-life experience. J Dermatolog
Treat. 2020:1-5.
5. Maliyar K, O’Toole A, Gooderham MJ. Long-term single center
experience in treating plaque psoriasis with guselkumab. J
Cutan Med Surg. 2020;24(6):588-595.
https://doi.org/10.1016/j.jdin.2021.05.001
